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In Reply to Helms: In the article
by Helms et al., Helms concludes that
infections with Salmonella  Typhim-
urium strains resistant to ampicillin,
chloramphenicol, streptomycin, sul-
fonamide, and tetracycline (hereafter
referred to as penta-resistant) were
associated with higher death rates than
infections with non–penta-resistant S.
Typhimurium. Helms also concluded
that infections with quinolone-resist-
ant (nalidixine-resistant) S. Typhimu-
rium were associated with higher
death rates than quinolone-susceptible
S. Typhimurium (1).
Table 2 in Helms’ article provides
information that enables close scruti-
ny of this conclusion and comparison
of the excess mortality associated
with penta-resistant, quinolone-sus-
ceptible  S.  Typhimurium with the
excess mortality of non–penta-resist-
ant S. Typhimurium (1). In this letter,
the Table is based on the original
table. However, two additional com-
parisons have been added: the p val-
ues, which are not based on the data
but are approximations based on the
parameters in the table. 
The conclusion is that only
quinolone resistance is associated
with excess mortality compared with
nonresistant isolates. Penta-resistant,
quinolone-susceptible  S.  Typhim-
urium has a risk ratio of 2.9 (1.1 to
7.9) compared to the ratio of
non–penta-resistant isolates 2.1 (1.5
to 2.9). When these figures are com-
pared, the approximate p value is
0.55, which, of course, is far from
being significant. Thus, on the basis
of the article by Helms, penta resist-
ance may not pose a greater threat to
human health than non–penta resist-
ance. However, the measured effect of
penta resistance is achieved by the
inclusion of quinolone-resistant S.
Typhimurium in the group. 
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In Reply to Dahl: The emergence
and spread of multidrug-resistant
Salmonella enterica  serovar
Typhimurium DT104 (MDR DT104)
contributed to an international
increase in antimicrobial drug resist-
ance in S. Typhimurium in the late
1990s (1,2). This type of Salmonella
is usually resistant to five drugs:
ampicillin, chloramphenicol, strepto-
mycin, sulfonamides, and tetracycline
(R-type ACSSuT) and easily acquires
resistance to other drugs, including
quinolones, trimethoprim, and amino-
glycosides (1,3–5). To determine
death rates after infection with MDR
DT104 or closely related strains, we
identified patients who were infected
with strains at least resistant to
ACSSuT (6). Analysis limited to
strains that were only R-type ACSSuT
would have given a misleading result
since MDR DT104 often, as men-
tioned, develops additional resistance
to other classes of antimicrobial drugs
in addition to the ACSSuT-complex.
This fact needs to be taken into
account in any attempt to quantify the
overall public health impact of MDR
DT104 and related strains.
We found, in our matched cohort
study (6), that 283 patients infected
with strains resistant to at least
ACSSuT were 4.8 times more likely
to die than the general Danish popula-
tion, compared with 2.3 for 953
patients infected with pansusceptible
strains. This difference in death rates
ocurred mainly because 40 of the 283
strains had R-type ACSSuTNx (i.e.,
additional resistance to nalidixic
acid), and infection with this strain in
particular is associated with a high
death rate (relative mortality 13.1). As
Dahl suggests, infection with R-type
ACSSuT (Nx susceptible) was not
Table. Table showing additional comparisons (1)
a 
Resistant  Susceptible 
 
Deaths/ 
cases  RR
b  (95% CI) 
Deaths/ 
cases  RR
b (95 % CI)  p value 
Penta with and 
without quinolone 
12/283  4.8 (2.2 to 10.5)  47/1,764  2.1 (1.5 to 2.9)  0.06 
Penta with 
quinolone 
5/40  13.1 (3.3 to 51.9)  47/1,764  2.1 (1.5 to 2.9)
c  0.01
d 
Penta without 
quinolone 
7/243  2.9 (1.1 to 7.9)  47/1764  2.1 (1.5 to 2.9)
c  0.55c
d 
aRR, relative risk; CI, confidence interval. 
bAdjusted for coexisting conditions.
 
cCompared to the non-penta group. 
dApproximations based on the parameters from the table. Emerging Infectious Diseases • Vol. 9, No. 10, October 2003 1351
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associated with excess mortality in the
243 patients included in the analysis,
and the measured effect of ACSSuT
was achieved by the inclusion of the
nalidixic acid–resistant strains in this
group. However, all deaths associated
with nalidixic acid–resistant strains
occurred in the 40 patients with R-
type ACSSuTNx (being DT104s),
whereas none of the 43 patients infect-
ed with non-ACSSuT strains resistant
to nalidixic acid died. This finding
may be related to small numbers in
these subanalyses. However, because
25 of the patients with R-type
ACSSuTNx were part of an outbreak,
they may have had an average higher
exposure dose, which may have con-
tributed to some deaths (3). In addi-
tion, an interaction between different
resistance traits in Salmonella may
exist, which may lead to more deaths
and disease, or DT104 may be some-
what more virulent than most other S.
Typhimurium subtypes.
The database that we used for our
analysis was updated in May 2002.
We have now identified 13 deaths in
342 patients infected with strains
resistant to ACSSuT (but Nx suscepti-
ble), which corresponds to a relative
mortality rate of 4.18 (95% confi-
dence interval [CI]) 2.18 to 8.02)
compared with a matched sample of
the general population. Of 1,432
patients infected with pansusceptible
strains, 43 patients died (relative mor-
tality rate 2.64; 95% CI 1.88 to 3.70).
In other words, the mortality rate in
patients infected with strains resistant
to ACSSuT (Nx susceptible) was 1.6
times higher than in patients with pan-
susceptible strains (p value for homo-
geneity 0.22). These estimates were
not adjusted for coexisting conditions
as were the estimates in the paper (6). 
We agree with Dahl that particular
problems are associated with
quinolone resistance in zoonotic sal-
monellae and that fluoroquinolones
may have reduced efficacy to treat
patients infected with Salmonella
strains that are nalidixic acid
(quinolone) resistant (7). We therefore
encourage initiatives to preserve the
efficacy of fluoroquinolones, includ-
ing a limitation of their use in agricul-
ture. Whether infection with S.
Typhimurium R-type ACSSuT, with
no additional resistance, is associated
with higher disease or death rates than
pansusceptible  S. Typhimurium
remains unclear. Although the differ-
ence was not significant (p=0.22), our
recent estimates suggest that the death
rate is approximately 60% higher in
patients infected with such strains.
This view is corroborated by recent
studies from the United States, which
suggest that S. Typhimurium R-type
ACSSuT is associated with an
increased risk for blood stream infec-
tion (8) and that resistance in nonty-
phoid  Salmonella is associated with
an increased risk for admission to hos-
pital (9).
Morten Helms,* Pernille Vastrup,*
and Kåre Mølbak*
*Statens Serum Institut, Copenhagen,
Denmark 
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Serogroup A
Neisseria 
meningitidis
Outside Meningitis
Belt in Southwest
Cameroon 
To the Editor: Epidemic meningi-
tis associated with serogroup A
Neisseria meningitidis is a devastat-
ing disease in the absence of vaccina-
tion (1). Without treatment, the case-
fatality rate is high, approaching
100%. In Africa, such epidemics
occur regularly (1) within a well-lim-
ited geographic zone, the so-called